Nintedanib Ipf Al

Nintedanib, the active ingredient in Nintedanib Ipf Al, is a tyrosine kinase inhibitor presented as an oral formulation for oral use. It treats idiopathic pulmonary fibrosis, systemic sclerosis‑associated interstitial lung disease, and non‑small cell lung cancer in appropriate patients.

GNH USA supplies Nintedanib Ipf Al as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. Our distribution network complies with global quality standards, ensuring reliable delivery to healthcare institutions across Europe, Asia, Africa and the Americas.

Nintedanib is indicated for several fibrotic lung conditions and certain cancers, where it targets disease‑driving pathways.

- Idiopathic pulmonary fibrosis: slows disease progression and reduces decline in lung function. - Systemic sclerosis‑associated interstitial lung disease: helps preserve lung capacity and delays worsening. - Non‑small cell lung cancer: used in combination therapy to inhibit tumor growth.

Nintedanib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Diarrhea: frequent loose stools. - Vomiting: occasional emesis. - Decreased appetite: reduced desire to eat. - Abdominal pain: discomfort in the stomach area. - Elevated liver enzymes: mild increase in hepatic labs.

Serious or Rare Side Effects: - Hepatic failure: severe liver injury requiring monitoring. - Major bleeding: gastrointestinal or intracranial hemorrhage. - Cardiovascular events: myocardial infarction or stroke. - Gastrointestinal perforation: rare but serious ulceration. - Severe infections: opportunistic infections in immunocompromised patients.

Before initiating therapy, clinicians should assess baseline organ function and consider potential risks.

- Liver function monitoring: check ALT/AST before and during treatment. - Bleeding risk assessment: evaluate concomitant anticoagulant or antiplatelet use. - Cardiovascular evaluation: screen for history of ischemic heart disease. - Pregnancy and lactation: avoid use; safety not established. - Severe hepatic impairment: contraindicated or requires dose adjustment. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Nintedanib can interact with several drug classes; careful review of a patient’s medication list is essential.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase nintedanib exposure. - Anticoagulants (e.g., warfarin): heightened risk of bleeding. - High‑dose aspirin or other antiplatelet agents: increased bleeding tendency.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inducers (e.g., rifampicin): may reduce efficacy. - P‑gp inhibitors (e.g., verapamil): may raise plasma levels. - Diuretics: monitor for dehydration and renal function.